Content area

|
|

Behandling med inhalationssteroid øger risiko for pneumoni ved kronisk obstruktiv lungesygdom

Mellemlapspneumoni hos en patient med kronisk obstruktiv lungesygdom.
Forfatter(e)
Mads Lumholdt1, Janni Vagner Steenholt1 & Jørgen Vestbo1, 2 1) Klinisk Institut, Det Sundhedsvidenskabelige Fakultet, Syddansk Universitet 2) Lungemedicinsk Afdeling J, Odense Universitetshospital Ugeskr Læger 2014;176:V03140137
Reference: 
Ugeskr Læger 2014;176:V03140137
Blad nummer: 
Sidetal: 
1700-1703
Inhaled corticosteroid treatment increases the risk of pneumonia in patients with CPOD
Clinical studies have suggested that inhaled corticosteroid (ICS) increases the frequency of pneumonia in patients with chronic obstructive pulmonary disease (COPD). This article summarizes the risk of pneumonia by reviewing the largest clinical studies addressing pneumonia as an adverse effect of ICS treatment. The collected data show that treatment of COPD patients with ICS increases the rate of pneumonia compared with β2-agonists or placebo. Physicians are recommended to follow guidelines and solely treat COPD patients with ICS if the patients are at high risk of exacerbations.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Christian Søren Christiansen | 19/11
2 kommentarer
af Pål Ledaal | 18/11
3 kommentarer
af Hanne Pedersen | 17/11
1 Kommentar
af Mads Aage Toft Kristensen | 16/11
1 Kommentar
af Ketil Bjerregård | 15/11
1 Kommentar
af Jens Lund Ahrenkiel | 15/11
1 Kommentar
af Nicolaj Markus Stilling | 15/11
2 kommentarer